MohamadKassarMD

Oncology • Dyer, IN

Physician

Join to view full profile

Dr. Kassar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Kassar's full profile

Already have an account?

Office
1001 Calumet Ave
Dyer, IN 46311
Phone+1 219-924-8178

Fax+1 219-924-8179
Is this information wrong?

Education & Training

Rush University Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
Yale-New Haven Medical CenterResidency, Internal Medicine, 2001 - 2004
Damascus University Faculty of MedicineClass of 1999

Certifications & Licensure

IN State Medical License 2007 - 2025
IL State Medical License 2005 - 2011
CT State Medical License 2004 - 2005
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
Active, not recruiting
Phase 3
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 3
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23
Active, not recruiting
Phase 3
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Start of enrollment: 2009 Jun 29
Active, not recruiting
Phase 3
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2009 Aug 17
Active, not recruiting
Phase 3
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry Start of enrollment: 2015 Nov 01
Completed
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Incorporating targeted therapy into conditioning regimen for patients undergoing autologous stem cell transplant (ASCT) for aggressive CD20 positive B-cell lymphoma ha...
Farhat M, Metzner I, Gregory SA, Venugopal P, Kassar M, Karmali R, Maciejewski J, Fung HC> ;J. Clin. Oncol.. 2008-05-20
20 citations
Outpatient high‐dose melphalan in multiple myeloma patients
Mohamad Kassar, Erin Medoff, Stuart Seropian, Dennis L. Cooper> ;Transfusion. 2007 Jan 1
116 citations
Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer
Amanda Psyrri, Mohamad Kassar, Ziwei Yu, Aris Bamias, Paul M. Weinberger, Sonia Markakis, Diane Kowalski, Robert L. Camp, David L. Rimm, Meletios A. Dimopoulos> ;Clinical Cancer Research. 2005 Dec 15
31 citations
Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer.
Amanda Psyrri, Aris Bamias, Ziwei Yu, Paul M. Weinberger, Mohamad Kassar, Sophia Markakis, Diane Kowalski, Eleni Efstathiou, Robert L. Camp, David L. Rimm, Meletios A....> ;Clinical Cancer Research. 2005 Dec 1
65 citations
Cisplatin, Fluorouracil, and Leucovorin Induction Chemotherapy Followed by Concurrent Cisplatin Chemoradiotherapy for Organ Preservation and Cure in Patients With Adva...
Amanda Psyrri, Myron S. Kwong, Susan A. DiStasio, L. Lekakis, Mohamad Kassar, Clarence T. Sasaki, Lynn D. Wilson, Bruce G. Haffty, Yung H. Son, Douglas A. Ross, Paul M...> ;Journal of Clinical Oncology. 2004 Aug 1
Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front...
Karmali, R., Kassar, M., Venugopal, P., Shammo, J. M., Fung, H. C., Bayer, R., O'Brien, T., Gregory, S. A.> ;Clin Lymphoma Myeloma Leuk. 2011 Dec
Join now to see all

Press Mentions

The US Oncology Network Continues to Grow, Enhancing Community Cancer Care by Welcoming Two More PracticesOctober 22nd, 2020

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

Community HospitalMunster, Indiana
Northwest Health -PorterValparaiso, Indiana
Franciscan Health HammondHammond, Indiana

MohamadKassarMD

Dr. Kassar is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Professional Memberships

Hospital Affiliations

Viewing the full profile is available to verified healthcare professionals only.